Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax combined with tamoxifen in relapsed/refractory diffuse large B-cell lymphoma
2020-005515-51Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and tamoxifen in diffuse large B-cell lymphoma (DLBCL), sponsored by University Medical Center Groningen. Primary endpoint: Safety and toxicity. Started Jun 2021; status: active.
02
Drugs
venetoclaxtamoxifen
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2020-005515-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005515-51.